Clinical efficacy of cefoperazone and Shubatan in the treatment of severe acute infection
10.3969/j.issn.1005-1678.2017.10.088
- VernacularTitle:头孢哌酮联合舒巴坦治疗急诊重症感染的临床疗效研究
- Author:
yang Chui ZHOU
1
;
lei Lei XIA
;
xian Ren GAO
;
qing Da CHEN
Author Information
1. 温州医科大学温州市第三临床学院 温州市人民医院 急诊科
- Keywords:
cefoperazone;
Shubatan;
emergency severe infection;
clinical efficacy
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(10):209-210
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate and analyze the clinical efficacy of cefoperazone and Shubatan in the treatment of severe infection in emergency department. Methods 100 cases of severe infection were randomly divided into control group and experimental group, with 50 patients in each group. The control group received routine treatment, and the experimental group was treated with cefoperazone and Shubatan on this basis. Pay close attention to the related vital signs change of the experimental group and the control group, the relevant clinical indicators of the two groups of patients were compared and analyzed. Results After the corresponding treatment, the bacteria removal rate of the experimental group was 90.00%, significantly higher thant 60.00 % of the control group (P<0.05). The effective rate of the experimental group was 90.00%, which was significantly higher than that of the control group (74.00%), which was statistically significant (P<0.05). There were no obvious adverse reactions in the two groups. After treatment, the total score of quality of life in the experimental group was (75.2±11.2) points, and the total score of QOL in the control group was (64.2±9.3) points, which was statistically significant (P<0.05). Conclusion The clinical efficacy of cefoperazone and Shubatan in the treatment of emergency severe infection is satisfactory. It can significantly improve the clinical symptoms and improve the quality of life in patients with severe acute respiratory infection.
